Development of in house methodology for the determination of plasma soluble urokinase plasminogen activator receptor (suPAR)

Abstract

The glomerulopathies are among the leading causes of end-stage renal disease and although numerous treatments are available, there is a growing need for early diagnosis. Then it is important the study of sensitive biomarkers and easy handling in clinical routine to detect the activity of these diseases, including episodes of reactivation. The plasma soluble urokinase plasminogen activator receptor (suPAR) is a biomarker that has been described in the literature as promising in determining disease activity with periods of remission and activation, such as Systemic Lupus Erythematosus (SLE). The kit available for dosages of suPAR is very expensive, thus is inadequate for diagnosis and follow-up of patients in clinical practice. Therefore, the development and validation of the "in house" method for suPAR dosage would enable a more detailed study of the usefulness of this marker.Objectives: this project proposes the development of the "in house" method for determination of suPAR. In addition to defining the criteria for validation, we will apply it in a group of SLE patients and determine the reference values. Material and methods: serum and urine samples will be collected from female patients with SLE with varying degrees of clinical and laboratorial activity of the disease. It will be used the kit DuoSet ELISA Development System human uPAR, which contains basic reagents needed for the development of a immunoenzymometric assay. (AU)